FDA Approves Treatment for Rare Blood Disease

FDA Approves Treatment for Rare Blood Disease

The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, two years of age and older. “Prior to today’s approval, there had...

Pin It on Pinterest